CareSuperb COVID-19 Antigen Test Usability

COVID-19 Clinical Trial

Official title:

CareSuperb COVID-19 Antigen Home Test Usability Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05629455
• Other study ID #: AB-1001
• Status: Completed
• Phase: N/A
• Start date: November 17, 2022
• Est. completion date: November 22, 2022

Study information

• Verified date: February 2023
• Source: AccessBio, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test in Home Use.

Description:

COVID-19 is a contagious respiratory illness, caused by infection with the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This communicable disease is easily transmitted through aerosolized droplets containing the infectious virus. Infections with SARS-CoV-2 can have varying degrees of signs and symptoms, ranging from asymptomatic to severe. Individuals infected with SARS-CoV-2 are believed to be contagious from as early as two days prior to symptom onset to at least ten days after the onset of symptoms. The rapid detection of infections and contacts and the implementation of infection control measures are critical for mitigation of this virus.

The CareSuperb COVID-19 Antigen Home Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult lay user-collected anterior nares swab samples from individuals aged 2 to 13 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 22, 2022
• Est. primary completion date: November 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion criteria:

1. An Institutional Review Board (IRB) approved informed consent / assent, if applicable, is signed and dated prior to any study-related activities.

2. Male and female subjects 2 years of age and older.

3. Subject is willing to provide a self-collected nasal swab sample. (If the subject is under the age of 14, an adult lay-user will collect the sample.)

4. Subject agrees to complete all aspects of the study.

Exclusion criteria:

1. Subject has a visual impairment that cannot be restored with glasses or contact lenses.

2. Subject has prior medical or laboratory training.

3. Subject uses home diagnostics, e.g., glucose meters, HIV tests.

4. Subject has prior knowledge of their current COVID-19 infection status.

Related Conditions & MeSH terms

• COVID-19

Intervention

Device:
• CareSuperb COVID-19 Antigen Home Test Kit
At home COVID-19 antigen test kit

Locations

Country	Name	City	State
United States	L&A Morales Healthcare Inc.	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AccessBio, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Usability of Quick Reference Instruction	Primary Endpoints: 1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation.	One month
Primary	Usability of Test Kit	Primary Endpoints: 2. Assess the usability of the kit for home use based upon subject evaluation.	One month